Sensei Biotherapeutics (SNSE) Stock Price, News & Analysis

Company Overview

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways. In addition to these clinical-stage candidates, Sensei is advancing preclinical projects against novel innate immune checkpoints and exploring combination regimens to broaden therapeutic impact.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Sensei Biotherapeutics operates across the United States and collaborates with academic and industry partners to accelerate research and development. The company’s leadership team brings extensive experience in antibody therapeutics, translational research and clinical development, supporting its mission to bring innovative immunotherapies through clinical trials and deliver new treatment options for patients worldwide.

Key Stats

• Today's Range: N/A
• 50-Day Range: $10.79 to $32.62
• 52-Week Range: N/A
• Volume: 219,729 shs
• Average Volume: 53,599 shs
• Market Capitalization: $18.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $48.00
• Consensus Rating: Hold

Sensei Biotherapeutics Stock Analysis - MarketRank™

Sensei Biotherapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 605th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Sensei Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Sensei Biotherapeutics has a consensus price target of $48.00, representing about ∞ upside from its current price of $0.00.

Amount of Analyst Coverage

Sensei Biotherapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sensei Biotherapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sensei Biotherapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

63.96% of the float of Sensei Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sensei Biotherapeutics has a short interest ratio ("days to cover") of 20.65, which indicates bearish sentiment.

Change versus previous month

Short interest in Sensei Biotherapeutics has recently decreased by 2.12%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sensei Biotherapeutics does not currently pay a dividend.

Dividend Growth

Sensei Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Sensei Biotherapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for SNSE on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Sensei Biotherapeutics insiders have bought 11.35% more of their company's stock than they have sold. Specifically, they have bought $1,341,669.00 in company stock and sold $1,204,939.00 in company stock.

Percentage Held by Insiders

7.00% of the stock of Sensei Biotherapeutics is held by insiders.

Percentage Held by Institutions

10.50% of the stock of Sensei Biotherapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/21/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNSE
• CIK: 1829802
• Web: www.senseibio.com
• Phone: 240-243-8000
• Fax: N/A
• Employees: 40
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Sensei Biotherapeutics: $48.00
• High Price Target: $55.00
• Low Price Target: $30.00
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($142.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -83.59%
• Return on Assets: -256.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.39
• Quick Ratio: 14.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.74 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,342,000
• Free Float: 1,248,000
• Market Cap: $18.98 million
• Optionable: Not Optionable
• Beta: -0.25